|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | C12N 15/113 | (2010.01) |
| A61K 38/17 | (2006.01) | ||
| A61P 41/00 | (2006.01) | ||
| A61P 19/02 | (2006.01) |
| (11) | Patento numeris | 2238250 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 08866608.6 |
| Europos patento paraiškos padavimo data | 2008-12-22 | |
| (97) | Europos patento paraiškos paskelbimo data | 2010-10-13 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2017-07-19 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/US2008/014020 |
| Data | 2008-12-22 |
| (87) | Numeris | WO 2009/085269 |
| Data | 2009-07-09 |
| (30) | Numeris | Data | Šalis |
| 8660 P | 2007-12-21 | US |
| (72) |
BECKER, David, L., GB
GREEN, Colin, R., NZ
DUFT, Bradford, J., US
|
| (73) |
Ocunexus Therapeutics, Inc.,
12481 High Bluff Drive, Suite 150, San Diego CA 92130,
US
|
| (54) | USE OF ANTI-CONNEXIN 43 POLYNUCLEOTIDES, PEPTIDES OR ANTIBODIES FOR THE TREATMENT OF ORTHOPEDIC CONDITIONS |
| USE OF ANTI-CONNEXIN 43 POLYNUCLEOTIDES, PEPTIDES OR ANTIBODIES FOR THE TREATMENT OF ORTHOPEDIC CONDITIONS |